APATINIB-INDUCED HYPERTENSION ASSOCIATED WITH BETTER PROGNOSIS IN PATIENT WITH SOLID TUMOR

阿帕蒂尼 医学 内科学 单变量分析 癌症 入射(几何) 蛋白尿 肺癌 肿瘤科 胃肠病学 多元分析 物理 光学
作者
Caie Li,Liping Ma,Qiongying Wang,Xu Zhao,Ruixin Ma,Ningyin Li,Jing Yu
出处
期刊:Journal of Hypertension [Lippincott Williams & Wilkins]
卷期号:39 (Supplement 1): e153-e153
标识
DOI:10.1097/01.hjh.0000746056.15733.03
摘要

Objective: To investigate the incidence of apatinib-induced hypertension (HTN) in the treatment of patients with solid tumor in real world and to determine whether apatinib-induced HTN is associated with its anti-tumor efficacy. Design and method: We retrospectively collected the medical records of patients with solid tumor treated with apatinib in Lanzhou University Second Hospital and Gansu Provincial Cancer Hospital, from Oct 1st 2014 to Jun 30st 2019. The patients were then prospectively followed to determine the disease state, time of disease progression and death, as well as whether or not have newly initiated HTN. The mean follow-up was 16.5month, with the longest follow-up of 48 months. The apatinib-induced HTN was defined as either newly initiated HTN in patients with normal blood pressure or increases of antihypertensive intensity in patients with pre-existed HTN. The prognosis of patients was estimated with progression-free survival (PFS) and overall survival (OS). Results: A total of 400 patients were enrolled, of whom 136 (34%) were diagnosed with HTN induced by apatinib. The primary tumor in 40% of the patients were gastrointestinal cancer, followed by hepatobiliary cancer (14.5%) and lung cancer (13.3%). Patients in HTN group were older (p = 0.03), more frequently with proteinuria (p = 0.035) and higher dosage of apatinib (p = 0.024). The survival analysis showed that apatinib-induced HTN was associated with significantly longer PFS, as well as OS (both p < 0.01), the differences existed both in univariate and multivariate analyses. The subgroup analyses were performed in patients with gastrointestinal cancer, hepatobiliary cancer, and lung cancer, all showed consistent results. Conclusions: HTN is one of the most common side effects of apatinib in the treatment of solid tumors, with an incidence of as high as 34% in real world. Apatinib-induced HTN is significantly associated with better anti-tumor efficacy in patients with solid tumors. Given that there is still no effective predictive biomarker for apatinib, drug-induced HTN may be used as an surrogate one. The development of new antihypertensive drugs with better antihypertensive effects while no influences on antitumor activity, is in urgent need.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
之_ZH完成签到 ,获得积分10
1秒前
gds2021完成签到 ,获得积分10
3秒前
你好呀嘻嘻完成签到 ,获得积分10
3秒前
梅特卡夫完成签到,获得积分10
5秒前
熊雅完成签到,获得积分10
6秒前
8秒前
睡到自然醒完成签到 ,获得积分10
9秒前
cis2014完成签到,获得积分10
11秒前
独特的大有完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助10
12秒前
14秒前
xingyi完成签到,获得积分10
16秒前
17秒前
舒心的秋荷完成签到 ,获得积分10
20秒前
zz123发布了新的文献求助10
21秒前
liaomr完成签到 ,获得积分10
21秒前
粗犷的灵松完成签到,获得积分10
22秒前
吃小孩的妖怪完成签到 ,获得积分10
22秒前
ncuwzq完成签到,获得积分10
24秒前
yshj完成签到 ,获得积分10
25秒前
27秒前
净禅完成签到 ,获得积分10
29秒前
31秒前
迷人的寒风完成签到,获得积分10
32秒前
32秒前
water应助科研通管家采纳,获得10
33秒前
Lucas应助HHHAN采纳,获得10
35秒前
无情修杰完成签到 ,获得积分10
36秒前
小柒完成签到 ,获得积分10
38秒前
聪慧芷巧发布了新的文献求助10
39秒前
40秒前
44秒前
蓝意完成签到,获得积分0
45秒前
xiaohongmao完成签到,获得积分10
50秒前
53秒前
qweerrtt完成签到,获得积分10
1分钟前
1分钟前
与共发布了新的文献求助10
1分钟前
carly完成签到 ,获得积分10
1分钟前
颢懿完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022